...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vox Sanguinis: International Journal of Blood Transfusion and Immunohaematology >Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light
【24h】

Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light

机译：三种新兴病毒 - 严重急性呼吸综合征冠状病毒，克里米亚 - 刚果出血热病毒和NIPAH病毒 - 亚甲基蓝加可见光的血小板浓缩物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety. In this study, the ability of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate these viruses in platelet concentrates and plasma, respectively, was investigated. Materials and methods Blood products were spiked with SARS-CoV, CCHFV or NiV, and then treated with increasing doses of UVC light (THERAFLEX UV-Platelets) or with methylene blue (MB) plus increasing doses of visible light (MB/light; THERAFLEX MB-Plasma). Samples were taken before and after treatment with each illumination dose and tested for residual infectivity. Results Treatment with half to three-fourths of the full UVC dose (0 center dot 2 J/cm(2)) reduced the infectivity of SARS-CoV (>= 3 center dot 4 log), CCHFV (>= 2 center dot 2 log) and NiV (>= 4 center dot 3 log) to the limit of detection (LOD) in platelet concentrates, and treatment with MB and a fourth of the full light dose (120 J/cm(2)) decreased that of SARS-CoV (>= 3 center dot 1 log), CCHFV (>= 3 center dot 2 log) and NiV (>= 2 center dot 7 log) to the LOD in plasma. Conclusion Our study demonstrates that both THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce the infectivity of SARS-CoV, CCHFV and NiV in platelet concentrates and plasma, respectively.
机译：背景技术已经鉴定出严重急性呼吸综合征冠状病毒（SARS-COV），克里米加刚果出血热病毒（CCHFV）和NIPAH病毒（NIPAH病毒（NIV），以对输血安全构成潜在的威胁。在该研究中，研究了Theraflex紫外 - 血小板和TheraFlex MB - 血浆病原体灭活系统分别在血小板浓缩物和血浆中灭活这些病毒的能力。材料和方法用SARS-COV，CCHFV或NIV掺入血液产物，然后用增加剂量的UVC光（THEAFLEX UV-血小板）或用亚甲基蓝（MB）加上可见光剂量（MB / LIGHT; THEAFLEX MB-血浆）。用每个照明剂量进行处理之前和之后进行样品并测试残余感染性。结果用半左右四分之三的全UVC剂量处理（0中心点2 J / cm（2））降低了SARS-COV（> = 3中心点4对数）的感染性，CCHFV（> = 2中心点2血小板浓缩物中的检测极限（> = 4中心点3 log），用Mb处理和全光剂量的第四个（120 j / cm（2））降低，降低了SARS -cov（> = 3中心点1 log），cchfv（> = 3中心点2 log）和niv（> = 2中心点7 log）到等离子体中的LOD。结论我们的研究表明，TheraFlex紫外血小板（UVC）和TheraFlex MB - 血浆（MB / Light）分别有效地降低了血小板浓缩物和血浆中SARS-COV，CCHFV和NIV的感染性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号